HIF1A and neoplasm: To develop therapeutic agents targeting energy metabolism in the tumor microenvironment, we developed a series of potent new biguanide derivatives via structural modification of the aryl biguanide scaffold and screening using HIF-1- and UPR-dependent reporter assays and selective cytotoxicity assays under low glucose conditions.